医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Orthocell Announces Collaboration with Johnson & Johnson Innovation

2017年01月12日 AM09:32
このエントリーをはてなブックマークに追加


 

PERTH, Australia

Regenerative medicine company Orthocell Limited has today announced a research collaboration agreement with DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, for its Ortho-ATI® stem cell approach for the regeneration of degenerate tendons and ligaments. The collaboration was facilitated by Johnson & Johnson Innovation.

Ortho-ATI is a novel non-surgical approach to treat chronic treatment resistant tendon injuries that have a significant negative effect on patients’ activities of daily living.

A collaborative study is planned to commence in Q1 2017 and will be a multi-center trial conducted with one of Australia’s leading orthopaedic surgeons. The trial will be led by prominent Orthopaedic Surgeon, Professor Allan Wang from the University of Western Australia and current President of the ‘Shoulder and Elbow Society of Australia’ (SESA).

Managing Director Mr. Paul Anderson commented, “This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology.”

In studies conducted by Orthocell to date, Ortho-ATI has been shown to be a cost effective and durable non-surgical solution for difficult to treat tendon injuries. Ortho-ATI is available in Australia and New Zealand for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs and have ongoing symptoms.

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed Autologous cell therapies, Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170111006184/en/

CONTACT

General enquiries:
Orthocell Limited
Paul Anderson, +61
8 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor
relations:

WE Buchan
Ben Walsh, + 61 417 382 391
bwalsh@buchanwe.com.au
or
Media
enquiries:

WE Buchan
Amanda Loh, + 61 3 8866 1215
aloh@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • オクタファルマ:重度血友病Aの未治療患者がoctanate®を使用するとインヒビター発現率が低減
  • Octapharma:罹患重症血友病A的既往未曾治疗患者(PUP)使用octanate®后,抑制因子的发生率降低
  • Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year
  • 武田薬品:「世界で最も持続可能な100社」に3年連続で選出
  • GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m